The Institute of Technology of Paraná (Tecpar) will produce biologic drug Avastin, the latest generation for the fight against cancer and macular degeneration (vision loss) relative to age. The product uses the active ingredient of Avastin, Roche, whose patent expired in 2012. The production of the drug in Paraná was completed during a mission trip to Russia Tecpar, in order to finalize the details of the cooperation agreement signed between the institute and Biocad Brazil.

The meetings between the two parties took place in two cities of Russia - St. Petersburg and Moscow - with visits to the Biocad a Russian biotech company, whose focus is research, development, production, innovation, and marketing of pharmaceuticals of biological origin. These contacts served to start a schedule of technology transfer, from staff training to achieve production in the laboratory Tecpar, to be installed in the technology park of Maringa.

The Tecpar now passes to a new stage in its history. Known and respected for the development and production of biopharmaceuticals, now also part of the list of producers of biological art. It is a great challenge that lies ahead, helping to improve public health in the country says Julio Felix, CEO of Tecpar, who joined the mission to Russia Paraná.

The partnership between Tecpar Biocad and Brazil had already been formalized in a meeting at the Ministry of Health in Brasilia in June. On occasion, officers Tecpar presented to the Secretary of Science, Technology and the Ministry of Health, Carlos Gadelha, elaborate design among partners, as demand federal agency itself, from the first contacts for presentation to the possibility of a job set between the parties, which follows the model of Productive Development Partnership (PDP).

The Partnership for Productive Development aims to reduce the development time of new products, using technology transfer of the production process of strategic medicines that are already developed by private enterprise. The deadline for a PDP is five years, during which the product must have been registered in Brazil while all its stages of production should also be being held in the country.

By the official deadline that compromise between Tecpar Biocad and in 2017 the first products of the new laboratory to be installed will be delivered.

• Tweet